Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
Lívia Pimenta BonifácioEduardo RamacciottiLeandro Barile AgatiFernando Crivelenti VilarAnna Christina Tojal da SilvaPaulo Louzada JúniorBenedito Antônio Lopes da FonsecaHayala Cristina Cavenague de SouzaCaroline Candida Carvalho de OliveiraValéria Cristina Resende AguiarCarlos Augusto de Aguiar QuadrosCesar DusilekKengi ItinoseRicardo RissonLucas Roberto Rivabem FerreiraRenato Deláscio LopesEsper Georges KallásFernando Bellissimo-RodriguesPublished in: Revista da Sociedade Brasileira de Medicina Tropical (2023)
Ixekizumab, colchicine, and IL-2 were demonstrated to be safe but ineffective for COVID-19 treatment. These results must be interpreted cautiously because of the limited sample size.